Activin a inhibits antigen-induced allergy in murine epicutaneous sensitization. by Kypriotou, M. et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 22 August 2013
doi: 10.3389/fimmu.2013.00246
Activin A inhibits antigen-induced allergy in murine
epicutaneous sensitization
Magdalini Kypriotou1, Dianelys Rivero1, Sergio Haller 2, Anita Mariotto1, Marcel Huber 1, Hans Acha-Orbea2,
SabineWerner 3 and Daniel Hohl 1*
1 Laboratory of Cutaneous Biology, Service of Dermatology and Venereology, Beaumont Hospital, CHUV, Lausanne, Switzerland
2 Department of Biochemistry, University of Lausanne, Lausanne, Switzerland
3 Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland
Edited by:
Heiko Mühl, Goethe University
Frankfurt, Germany
Reviewed by:
Ralf J. Ludwig, University of Lübeck,
Germany
MiriamWittmann, University of
Leeds, UK
George Bougharios, University of
Oxford, UK
*Correspondence:
Daniel Hohl , Service of Dermatology
and Venereology, Beaumont Hospital,
CHUV, 04-437, Beaumont Avenue 29,
1011 Lausanne, Switzerland
e-mail: daniel.hohl@chuv.ch
Activin A, a member of theTGFβ superfamily, is involved in physiological processes such as
cell differentiation, tissue homeostasis, wound healing, reproduction, and in pathological
conditions, such as fibrosis, cancer, and asthma. Activin enhances mast cell maturation, as
well as regulatory T-cell and Langerhans cell differentiation. In this study we investigated
the potential role of activin in epicutaneous sensitization with ovalbumin (OVA), notably
with respect to its effect on known Th2-polarization. For this purpose, transgenic mice
overexpressing activin in keratinocytes and their wild-type (WT) controls were sensitized
epicutaneously with OVA. Skin biopsies were analyzed with regard to histopathological fea-
tures and mRNA expression of pro-inflammatory andTh1/Th2 cytokines, and Ig levels were
measured in the serum. Unexpectedly, activin overexpressing animals were protected from
Th2-cytokine expression and induction of OVA-specific IgE levels compared to WT animals.
On the other hand, transgenic mice were more susceptible to inflammation compared to
WT littermates after tape-stripping and saline (vehicle) or OVA application, as shown by
increased pro-inflammatory cytokine mRNA levels and neutrophil accumulation at the site
of the treatment. We conclude that activin protects from antigen-induced cutaneous Th2-
polarization through modulation of the immune response.These findings highlight the role
of activin in cutaneous sensitization, allergy, and in skin homeostasis.
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INTRODUCTION
Activins belong to the“transforming growth factor”(TGFβ) super-
family of cytokines and growth factors. The most abundant
activin variant is activin A, the homodimer formed by two βA
subunits connected by a disulfide bridge (1, 2). In addition to
the well-characterized dimers, activin A (βAβA), B (βBβB), and
AB (βAβB), two additional β chains (βC and βE) have been
described. Activins exert their biological effects through activa-
tion of transmembrane serine/threonine kinase receptors. Binding
to a type II activin receptor (ActRIIA or ActRIIB) leads to the
recruitment, phosphorylation, and activation of a type I activin
receptor (ActRIB=Alk4, or ActRIC=Alk7). This activates the
canonical signaling pathway via Smad proteins (Smad2/3/4; C.
Elegans SMA and Mothers against decapentaplegic homologs), or,
alternatively, mitogen-activated kinase pathways (MAPK). Activin
bioavailability is regulated by natural soluble inhibitors, such as
follistatin, follistatin-related protein (FRP), and inhibin, and by
membrane-bound proteins, such as betaglycan (in complex with
inhibin), crypto, and BAMBI (3). Activins were initially described
as reproductive hormones, but they also have important func-
tions in development, tissue homeostasis, and repair. Activins
enhance fibrosis and epidermal skin cancer, promote bone and
skin wound repair, and act as pro- or anti-inflammatory proteins
in a cell type and organ dependent manner. Thus, it is not sur-
prising that abnormalities in activin receptor expression and/or
signaling are associated with various human diseases (4, 5). Activin
has immunomodulatory functions and can have pro- or anti-
inflammatory activities (3, 5, 6). In skin, activin overexpression
enhances carcinogenesis through generation of a pro-tumorigenic
immune cell response (4). In addition, mice overexpressing activin
in keratinocytes (K14-Activin tg) of the epidermis and hair folli-
cles present abnormal keratinocyte differentiation in the tail skin,
enhanced wound repair and increased populations of regulatory
T-cells (Treg) (7–9). Further, activin induces Langerhans cell (LC)
differentiation (10), and follistatin overexpression in the epidermis
of transgenic mice leads to reduction of the LC population (11).
Finally, activin induces mast cell maturation and migration (12).
Thus, activin is linked to particular biological processes, known
to be involved in atopy, which made us wonder whether it could
exert an active role in atopic dermatitis (AD).
Atopic dermatitis is the most common inflammatory skin dis-
ease, affects 10–20% of children and 1–3% of adults, and pre-
disposes to asthma and allergic rhinitis (13). AD origins involve
genetic, immune, and environmental factors. Briefly, impaired
barrier function, which in 50% of the cases is caused by profi-
laggrin (FLG) gene mutations, favors the penetration of irritants
and allergens through the epidermis. This leads in the predisposed
host to activation of LC, and subsequently to an initial Th2 cell
polarization induced by specific cytokines, such as thymic stromal
lymphopoietin (TSLP) (14). Recently, activation of intraepithelial
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lymphocytes (dendritic epidermal T-cells in mice, DETCs) by anti-
gens expressed on stressed keratinocytes has been shown to con-
tribute to Th2 cell polarization (15). Migration of inflammatory
cells to the site of lesion and specific cytokine accumulation result
in a Th2 to Th1 switch and the“chronic”phase of AD,characterized
by keratinocyte hyperproliferation and epidermal thickening with
prominent infiltrates of LC, eosinophils, monocyte-macrophages,
and mast cells (16).
There is no current information about activin involvement in
human skin allergic diseases. However, this cytokine is strongly
associated with allergic asthma, one of the atopic diseases (17).
Airway epithelial barrier presents several common functional fea-
tures and immune reactivity with epidermal barrier. Therefore, we
undertook an in vivo study which investigates the potential role of
activin in a mouse model for allergic dermatitis (18, 19). Repeated
epicutaneous sensitization with ovalbumin (OVA) leads to AD-like
lesions in mice characterized by progressive thickening of dermis
and epidermis, and the presence of inflammatory infiltrates in the
skin. Further, epicutaneously OVA-treated mice develop an early
Th2-polarization, characterized by increased mRNA levels of IL4,
IL13, and IL5, and high levels of IgE and OVA-specific IgE, which
is another common feature of acute human AD. After 3 weeks
of OVA exposure, increased mRNA levels of IFNγ, IL12p35, and
OVA-specific IgG2a are observed, which is reminiscent of the Th2
(acute phase) to Th1 (chronic phase) switch of human AD (18, 20).
Ovalbumin sensitization of transgenic mice overexpressing
activin in keratinocytes led to Th2-independent inflammation.
Our data reveal that activin plays a protective role against antigen-
specific dermatitis and suggest that it is involved in the onset of
AD-like symptoms in an epicutaneous sensitization mouse model.
MATERIALS AND METHODS
MICE – OVA-EPICUTANEOUS SENSITIZATION
Wild-type (WT) CD1 (Crl:, Charles River, France), and K14-
Activin transgenic mice (K14-Act mice) (2, 4) were housed,
fed, and bred under SPF (Specific Pathogenic Free) conditions,
according to federal guidelines and the federal and local author-
ities approved procedures. Breeding was performed between WT
female and K14-Act tg male mice. WT and K14-Act tg female
littermates were used for the experiments. Four to six-week-old
female mice were treated according to the OVA-epicutaneous sen-
sitization protocol described previously (18). Briefly, at day 0 (d0),
mice were anesthetized, shaved and tape-stripped 12 times. A
1 cm2 piece of sterile gauze containing 100µl of OVA (Sigma,
Switzerland) (1 mg/ml in NaCl 0.9%) or 100µl of NaCl 0.9%
only (control – Ctl) was secured on the back with a bandage, left
for 7 days, then removed, this process followed by a 14-day rest
period. Epicutaneous sensitization with OVA was repeated three
times. The mice were sacrificed on day 50 (d50), and skin biopsies
and serum were collected. Four groups of mice [WT – vehicle-
treated (Ctl), WT OVA-treated, K14-Act vehicle-treated (Ctl), and
K14-Act OVA-treated], each including 10–15 mice, were used.
RNA EXTRACTION AND REAL-TIME RT-PCR
Total RNA from dorsal skin mouse biopsies was extracted using
the RNeasy Fibrous Tissue Mini Kit (Qiagen, Germany). RNA
integrity was verified on an agarose gel under denaturating
conditions. RNA (2µg) was reverse-transcribed into cDNA using
MMLV-reverse transcriptase (New England Biolabs, UK) as fol-
lows: 10 min at 25°C, 60 min at 42°C, 5 min at 95°C. Real-time PCR
analysis was performed on a StepOne™ PCR apparatus (Applied
Biosystems, UK) using a Power SYBR Green Master Mix (Applied
Biosystems, UK) and specific primers. Samples were amplified
as described (21). The primers were designed using the Roche
software (Universal Probe Library, Assay Design Center) unless
described differently (Table 1). Analysis of relative gene expres-
sion was performed using the 2−∆∆CT method (22). Hypoxan-
thine guanine phosphoribosyl transferase (Hprt ) mRNA was used
as internal control. Statistical analysis was performed with the
Mann–Whitney U -test.
HISTOLOGY
Dorsal skin biopsies were fixed overnight in freshly prepared PFA
4% (paraformaldehyde) at 4°C, then washed in TBS and embedded
in paraffin. Skin specimens of 5µm thickness were deparaffinized,
rehydrated, and stained with hematoxylin and eosin as described
(21). Stained sections were analyzed under the light microscope
(Nikon Ellipse E400, Switzerland) coupled to a CCD camera.
IMMUNOFLUORESCENCE
Dorsal skin biopsies were snap frozen in isopentane, embedded
in OCT and cut in 5µm cryosections. Specimens were fixed in
ice-cold acetone, blocked with 5% NGS (normal goat serum) –
TBS – GBA (glycine – BSA) for 1 h and incubated at room tem-
perature (RT) with the primary antibody – γδTCR-FITC antibody
(BD Biosciences San Diego, CA), anti-MPO (myeloperoxidase)
(Neomarkers, Thermo Scientific, Fremont – CA, USA), anti-F4/80
(Caltag Invitrogen AG, Camarillo, CA, USA), or anti-langerin
(CD207, clone 929F3.01, Dendritics, France). Three hours later,
slides were rinsed and incubated for 1 h with the appropriate
secondary antibody (Alexa Fluor 488 IgG, Molecular Probes, Invit-
rogen, Netherlands), when needed, then counterstained with DAPI
and mounted with a fluorescent mounting medium (Dako, Den-
mark). The images were captured by a confocal microscope (LSM
700 Zeiss, Switzerland) and analyzed using the ZEN2010 software.
γδTCR-, MPO-, F4/80-, or langerin-positive cells were counted
in 10–15 microscope fields (×20) per animal (five mice per group),
and expressed as cells per millimeter of basal layer or per square
millimeter of skin. Numbers in vehicle-treated WT animals were
used as reference. Mean and SD were calculated and statisti-
cally significant differences were calculated with Mann–Whitney
U -test.
ELISA
Detection of total IgE in serum was performed using a mouse IgE
ELISA Set (BD OptEIA, BD Biosciences Pharmingen, Belgium).
For OVA-specific IgE, a 96-well ELISA plate was coated with OVA
(40µg/ml) in sodium carbonate coating buffer overnight at 4°C.
After blocking with 10% heat inactivated FBS, mouse serum sam-
ples (diluted 1:20 for IgE) were added and incubated for 3 h at RT.
Biotinylated detection antibodies (rat anti-mouse IgE – clone R35-
118, BD Pharmingen, Belgium) and a streptavidin-HRP reagent
were used for detection.
Total serum Ig2a levels were detected using a sandwich
ELISA: briefly, the plate was coated with a capture antibody (rat
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Table 1 | Real-time PCR primers used in this study.
Target gene Forward Reverse GenBank accession number
Il1β TGAAGTTGACGGACCCCAAA TGATGTGCTGCTGCGAGATT NM_008361
Tnfα CCAGGCGGTGCCTATGTCT GGCCATTTGGGAACTTCTCAT NM_013693
Tslp TCCTATCCCTGGCTGCCCTTCA TGTGCCATTTCCTGAGTACCGTCA NM_021367
Il4 CATCGGCATTTTGAACGAG CGAGCTCACTCTCTGTGGTG NM_021283
Il13 CCTCTGACCCTTAAGGAGCTTAT CGTTGCACAGGGGAGTCT NM_008355
Ifnγ ATCTGGAGGAACTGGCAAAA TTCAAGACTTCAAAGAGTCTGAGGTA NM_008337.3
Il10 CAGAGCCACATGCTCCTAGA GTCCAGCTGGTCCTTTGTTT NM_010548.1
Il17A ACCCTGGACTCTCCACCGCA GTGCAGCCCACACCCACCAG NM_010552.3
Foxp3 AGAAGCTGGGAGCTATGCAG GCTACGATGCAGCAAGAGC NM_054039.1
Rae-1 TGGACACTCACAAGACCAATG CCCAGGTGGCACTAGGAGT NM_020030
Hprt GTTGGATACAGGCCAGACTTTGTTG GATTCAACTTGCGCTCATCTTAGGC NM_013556
anti-mouse IgG2a – clone R11-89, BD Pharmingen) overnight at
4°C, and serum samples were diluted 1:400 and incubated for 2 h
at RT. A biotinylated antibody (Rat anti-mouse IgG2a – clone R19-
15, BD Pharmingen) and streptavidin-HRP reagent were used for
detection.
Colorimetric reactions occurred with TMB substrate solution
(Invitrogen, Netherlands) after 30 min incubation in the dark.
Absorbance was measured at 450 nm corrected for absorbance
at 620 nm. Statistical analysis was performed with the Mann–
Whitney U -test.
RESULTS
OVA-EPICUTANEOUS SENSITIZATION OF K14-ACTIVIN tg MICE LEADS
TO INFLAMMATION AND EPIDERMAL THICKENING
After treatment of WT and K14-Act mice with either OVA or vehi-
cle, histological analysis showed important differences between
the four groups of mice, in terms of epidermis thickening and
immune cell populations (Figures 1 and 2). In WT OVA-treated
mice, the epidermis was thickened (2-fold) compared to WT
vehicle-treated mice, and displayed lymphocytic exocytosis and
parakeratotic hyperkeratosis (Figures 1A,B). Further, the dermis
from WT OVA-treated mice showed features of fibrosis, as well
as moderate infiltrates of lymphocytes, macrophages, and to a
lesser extent neutrophils (Figures 2A,B,D). Untreated back skin
from K14-Act mice is phenotypically normal (4), whereas vehicle-
treated skin from K14-Act mice was characterized by thickened
epidermis (2-fold) and dermis compared to vehicle-treated WT
mice (Figures 1A,B). Further, the epidermis of K14-Act OVA-
treated mice was thickened compared to vehicle-treated WT mice
(approximately 3-fold), and lymphocytic exocytosis and hyper-
parakeratosis were observed (Figures 1A,B). Inflammatory infil-
trates, essentially composed of neutrophils, were more abundant
in the dermis of K14-Act OVA-treated mice compared to the rest
of the groups (Figure 1A; Figures 2A,D). Numbers of LC and
Foxp3 mRNA, as an indicator of the Foxp3+ Treg cell population
in skin, were not altered at the end of the protocol in any group
(Figures 2C,D, and data not shown).
The expression of IL1β and TNFα was analyzed in order to
further characterize the local inflammatory response. In addi-
tion, we analyzed the expression of TSLP, a marker cytokine for
impaired barrier function and inducer of Th2-polarization. No
differences in Il1β, Tnfα, or Tslp mRNA levels were observed
between untreated WT and K14-Act mice (Figures 3C,D, and
data not shown). However, Il1β and Tslp mRNAs were significantly
increased in vehicle-treated K14-Act mice as compared to vehicle-
treated WT mice (Figures 3A,B). No changes on Tnfa mRNA were
observed between these two groups (data not shown). Obviously,
the enhanced expression of pro-inflammatory cytokines results
from the experimental protocol, including shaving, tape-stripping,
and bandage application, which induces a non-specific inflamma-
tory response to mechanical barrier injury and vehicle application.
Il1β and Tslp mRNAs were increased in the OVA-treated WT mice
compared to the vehicle-treated WT group (Figures 3A,B). Tnfa
mRNA was also mildly increased in the OVA-treated WT mice
compared to the saline-treated WT animals, but there was no
other significant difference when compared to other groups (data
not shown). Inflammation in vehicle- and OVA-treated transgenic
mice was associated with high local mRNA expression levels of
both Il1β and Tslp mRNAs, when compared to vehicle-treated
WT group (Figures 3A,B). However, while antigen application did
provoke a strong Il1β mRNA increase in K14-Act mice compared
to the saline-treated K14-Act, Tslp mRNA was already elevated
without OVA, and no further increase was noted by allergen sensi-
tization (Figures 3A,B). These results reveal that repeated vehicle
and OVA application provoked a differential cutaneous reaction,
which was translated into a divergent cytokine expression pattern.
Further, our data imply that activin overexpressing animals were
more susceptible to inflammation after mechanical stress.
REDUCED Th2-POLARIZATION IN K14-ACTIVIN MICE
Acute AD involves a hypersensitivity response associated with
Th2-polarization. Surprisingly, Il13 and Il4 mRNAs remained
unchanged in the K14-Act OVA-treated mice compared to vehicle-
treated WT and K14-Act mice. This is an activin-dependent effect
because the mRNAs of the same cytokines were increased in
WT OVA-treated mouse skin, as expected. These results sug-
gest that activin prevents a Th2-response to OVA stimulation
(Figures 4A,B).
Ifnγ mRNA expression, as a marker of Th1 response in skin
appearing in chronic AD stages, was similar for all groups of ani-
mals (Figure 4C) Consequently, these mice did not show signs of
chronic eczematous lesions during the experimental protocol.
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FIGURE 1 | OVA-epicutaneous sensitization leads to epidermal
thickening and inflammation. (A) WT and K14-Act mice were treated
with vehicle (Ctl) or OVA. Skin biopsies were stained for H&E (20×
objective). (B) Epidermal thickness (7–10 animals per group, five to
seven fields per animal) in micrometer was measured on H&E-stained
biopsies from the four experimental groups using a scaled ocular lens
on a light microscope. Mean values are represented as fold of the
mean value of WT vehicle group (Ctl)±SEM. Statistical differences
were calculated with the Mann–Whitney U -test (p<0.05*,
p<0.001***).
ACTIVIN OVEREXPRESSION HAMPERS THE PRODUCTION OF IgEs
To better dissect the involvement of activin in the OVA-
epicutaneous sensitization, serum IgEs and IgG2a levels were
measured. Serum IgEs were significantly increased only in the
WT OVA-treated mice, whereas they remained at the basal
level for the other three groups (Figure 5A). The discrete and
non-significant increase in the vehicle-treated and OVA-treated
K14-Act mice in comparison to the vehicle-treated WT ani-
mals indicates a role of mechanical barrier disruption in atopic
sensitization.
Ovalbumin-specific IgEs were increased only in the WT-OVA
mice group, and barely detectable in OVA-treated transgenic mice
(Figure 5B). Thus, activin inhibits the antigen-specific immune
response in this experimental setting.
Further, a minor increase was observed in total serum IgG2a, for
the OVA-treated K14-Act group compared to the K14-Act Ctl mice,
although OVA-specific IgG2a were not detectable (Figure 5C and
data not shown). Thus, activin is involved in non-specific poly-
clonal IgG2a modulation, without inducing a Th1-polarization,
which should be associated with higher levels of antigen-specific
IgG2a and increased concentrations of Ifnγ. In sum, activin
overexpression hampers the immune response by blocking IgE
production.
DEPLETION OF γδ T-CELLS FROM K14-ACT MOUSE EPIDERMIS AFTER
OVA SENSITIZATION
γδ T-cells are involved in the induction of Th2-response and IgE
production after tissue damage (23). To test whether activin may
involveγδT-cell mediated immune surveillance in this experimen-
tal setting, γδ T-cells were quantified. A strong reduction of the
epidermalγδT-cell population was noted in K14-Act animals, par-
ticularly after OVA treatment (Figure 6A). Further, mRNA levels
of Rae1 (Retinoic acid early 1), an NKG2D ligand, were found sig-
nificantly decreased in the K14-Act OVA group when compared
to the WT OVA mice (Figure 6B). Given that epidermal γδ T-
cell numbers in untreated K14-Act mice as compared with WT
mice are unaffected (4), our results suggest that activin obstructs
maintenance of γδ T-cells in hyperproliferative epidermis after
mechanical injury, and this is further enhanced by antigen expo-
sure. This significant depletion of the γδ T-cell population in the
K14-Act mice after epicutaneous sensitization may contribute to
the reduced allergic reaction.
UPREGULATION OF Il10 AND Il17 mRNA EXPRESSION IN OVA-TREATED
TRANSGENIC MICE
IL10’s main role is to suppress allergic responses, but it can also be
a Th2-effector cytokine, according to the molecular context (24,
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FIGURE 2 | Morphological and cell analysis of vehicle-treated and OVA-treated mice. Cryosections from the four experimental groups were obtained.
MPO+ (A), F4/80+ (B), and langherin+ cells (C) were labeled with the respective antibodies, and analyzed with a confocal microscope (20× objective). (D)
MPO, F4/80, or langerin-positive cells were quantified and statistic analysis was performed with the Mann–Whitney U -test (p<0.05* and p<0.001***).
25). Its expression was evaluated in dorsal skin biopsies obtained
from vehicle or OVA-treated mice, by real-time PCR. Interestingly,
Il10 mRNA expression was increased in OVA-treated K14-Act mice
compared to OVA-treated WT mice (Figure 7A). IL10 secretion
in the absence of Th2 cytokines, as for the OVA K14-Act mice
(Figure 4), strongly suggests a regulatory function, which could
explain the suppression of Th2-response and IgE production. IL10
mRNA expression is also increased in OVA-treated WT mice when
compared to Ctl WT mice; in this case, IL10 could be co-secreted
from Th2-cells (Figure 7A).
IL17A, mainly produced by Th17 cells but also by neutrophils
and other immune cells,was measured as a marker of tissue inflam-
mation and eventual TSLP-induced Th2-polarization inhibitor
(26). Il17A mRNA was significantly increased in OVA-treated
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FIGURE 3 | Expression of pro-inflammatory cytokines in vehicle and
OVA-treated mice. cDNAs were generated from WT and K14-Act mice and
real-time PCR was performed. mIL1β (A,C) and mTslp (B,D) mRNAs were
amplified using cDNAs from untreated WT and K14-Act mice (C,D) or treated
with vehicle or OVA (A,B). Ct values were normalized to expression levels of
the hprt house-keeping gene. The experiment was realized in groups of five
mice for the untreated and 8–10 mice for the vehicle- or OVA-treated mice.
Results are presented in a scatter graph and mean values±SEM are shown.
Statistical differences were calculated with the Mann–Whitney U -test
(p<0.05*, p<0.01**, and p< 0.001***).
K14-Act skin biopsies compared to OVA-treated WT samples,
suggesting the involvement of Th17-related cytokines in allergen
epicutaneous sensitization (Figure 7B).
DISCUSSION
In this study we demonstrated for the first time that epidermal
keratinocyte-derived activin protects from antigen-specific T-cell
immune response in an epicutaneous sensitization murine model,
because: (1) It inhibited Th2-polarization after antigen-induced
allergic dermatitis, (2) It hampered IgE and antigen-specific IgE
production in mouse serum, and (3) It led to decrease of γδ
T-cell population in injured skin. These findings are novel and
they provide further evidence about the role of activin in skin,
already known for its involvement in wound healing and, skin
morphogenesis and tumorigenesis (2, 4, 9, 27).
Ovalbumin-epicutaneous sensitization induces a Th2-specific
response characterized by high IgE production (19). This response
evolves during the time of treatment, and depends on the quantity
of the antigen absorbed (19, 20, 28). Activin strongly blocked this
response because in OVA sensitized K14-Act transgenic animals,
Th2-cytokine expression levels remained low, and total IgE and
antigen-specific IgE serum levels were not significantly changed
compared to vehicle-treated mice. In contrast, antigen-treated
WT mice developed high total and OVA-specific IgE responses,
associated with an increase in Th2-derived Il4 and Il13 mRNA
expression, as expected.
The mechanism through which activin regulates antigen sensi-
tization responses in skin is not elucidated. However, it is known
that activin is involved in the antigen presentation process (4, 8,
25, 29, 30). Further, activin A suppresses effector Th2, but also
Th1 immunity through generation of a specific subset of regu-
latory T-cells (25). Treg subsets regulate T-lymphocyte activation
and suppress eosinophil and mast cell responses, inducing allergen
peripheral tolerance and protecting from anaphylactic shock (31).
Activin-induced Tregs in mouse lung draining lymph node (DLN)
are CD4+CD25-Foxp3−, express IL10 and TGFβ1 and inhibit
CD11c+ DCs maturation (7, 8, 25). Indeed, in our experimen-
tal setting, Il10 mRNA was increased in the OVA-treated K14-Act
mice, which, in the absence of Th2-responses, may suggest the
action of Treg cells. Except from Treg cells, IL10 is also secreted by
macrophages, neutrophils, fibroblasts, and keratinocytes, together
with other cytokines, such as TNFα, IL1β, IL8, and IL6, as a con-
sequence of DNA damage or inflammation (32–34). However, the
specific cytokine and cell type profile detected in this study strongly
supports the immunosuppressive role of IL10 in these experi-
mental conditions. The above data suggest that activin inhibits
Th2-polarization in our model, through a Treg-dependent mech-
anism. The absence of a local Th1-polarization, in our study, does
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FIGURE 4 |Th2-specific cytokines increase upon OVA treatment of WT
mice but not of K14-Act mice. Skin biopsies from WT and K14-Act mice,
untreated or treated (vehicle-Ctl or OVA) were collected and used for RNA
isolation and subsequent generation of cDNA. Real-time PCRs were
performed using primers specific for (A) mIl13, (B) mIl4, and (C) mIfnγ. Ct
values were normalized to expression levels of the hprt house-keeping
gene. The experiment was realized in groups of 8–10 mice. Results are
presented in a scatter graph and mean values±SEM are shown.
Statistically significant differences were calculated with the Mann–Whitney
U -test (p<0.05*, p<0.01**, and p< 0.001***).
not exclude a broader activin-mediated suppressive effect on T-cell
responses.
This is the first report providing data about the function of
activin in antigen-induced cutaneous allergic reaction, which are
consistent with its protective role from atopic pulmonary dis-
ease (17, 25). Activin is increased in serum and in CD4+ T-cells
of patients with mild asthma, although there are no differences
between healthy subjects and severely affected patients (25, 35). It
is mainly secreted by immune, lung smooth muscle and epithe-
lial cells and enhances epithelial and alveolar cell proliferation,
promoting tissue remodeling after allergen exposure (35–38). In
parallel, it is involved in the maturation of DCs and dimin-
ishes their antigen presenting capacity to T-cells (30), indicating
that activin suppresses allergic reactions and maintains tissue
homeostasis.
Barrier disruption-induced Th2-polarization is often preceded
by increase of TSLP expression (28, 39). TSLP is an epithelial-
derived cytokine and signals through a heteromeric receptor
(TSLPR and IL7rα). It is involved in the activation and/or pro-
liferation of several immune cell populations, such as B and T
lymphocytes, basophils and eosinophils, and is essential for DC-
driven Th2-polarization after mechanical injury of the epidermal
barrier (28, 40, 41). TSLP gene transcription is activated by IL1β
and TNFα (42). In our experimental setting, Tslp mRNA expres-
sion was increased in all three experimental groups, compared
to WT Ctl mice, independently on the presence or not of antigen.
TSLP upregulation is likely to be independent on the IL1β increase
FIGURE 5 | Activin overexpression inhibits the production of IgEs after
OVA treatment. WT and K14-Act mice treated with OVA or vehicle were
sacrificed, and serum was collected. Total IgE (A), OVA-specific IgE (B), and
total IgG2a (C) ELISA were performed as described in Section “Materials
and Methods.” The data are presented as a scatter plot and mean values
are shown (n= 8–12). Statistically significant differences were calculated
with the Mann–Whitney U -test (p<0.05* and p<0.01**).
during epicutaneous sensitization, because the expression levels
of their mRNAs did not correlate in the different experimental
groups (Figures 3A,B). Indeed, Oyoshi et al. (28), showed a rapid
and transient accumulation of TSLP in skin after tape-stripping.
This suggests that different mechanisms are at work in our model
in order to maintain TSLP expression in skin in a chronic manner.
These observations lead to the conclusion that activin plays a
role downstream of TSLP and prevents Th2-cytokine expression.
Bogiatzi et al. (26) recently showed that TSLP’s capacity to induce
a Th2-response depends on the cytokine milieu, and is inhibited
when Th17-related cytokines are present. In line with this finding,
IL17, IL1β, and Smad signaling are positively modulated in OVA-
treated K14-Act tg mice in our experimental setting, suggesting
that activin intervenes during early immune responses.
Significant reduction of γδ T-cell population in vehicle and
OVA-treated K14-Act skin, compared to WT Ctl mice, is another
feature of the activin-induced Th2 allergic reaction inhibition.
Indeed, γδ T-cells were shown to be required for the upregulation
of Th2-derived cytokines after epicutaneous antigen sensitiza-
tion, and they dramatically modulate the production of total and
antigen-specific IgE (23). This link between lymphoid stress sur-
veillance and atopic response, is further associated to Rae-1, a
NKG2D membrane receptor ligand, which promotes γδ T-cell
activation (23). γδ T-cells or DETCs reside in the murine epi-
dermis and are activated after epithelial stress. They induce the
elimination of damaged keratinocytes and are involved in the
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FIGURE 6 | Activin overexpression causes γδT-cell depletion in the
epidermis after mechanical injury and allergic sensitization. (A) Dorsal
skin biopsies from the four experimental groups were collected, and
cryosections were obtained. Epidermal γδ-T-cells were analyzed with a
confocal microscope (20× objective). Stained cells were quantified and
statistical analysis was performed with the Mann–Whitney U -test (p<0.01
for ** and p<0.001 for ***). (B) Real-time PCR was performed using
primers specific for mRae-1. Ct values were normalized to expression levels
of the hprt house-keeping gene. The experiment was realized in groups of
8–10 mice for the sensitized mice. Results are presented in a scatter graph
and mean values±SEM are shown. Statistically significant differences
were calculated with the Mann–Whitney U -test (p<0.05*).
activation of adaptive immunity (43, 44). Intraepidermal γδ T-
cells in human skin contribute to efficient wound repair, although
they are more scarce compared to mouse skin (45). The decrease
of intraepidermal γδ T-cells in vehicle-treated K14-Act mice, and
most importantly in the OVA-treated group is consistent with
reduced expression levels of Rae-1 mRNA. Thus, activin may not
only affect γδ T-cells, but also the expression of the activating
ligand on keratinocytes. Conversely, the γδ T-cell population (and
Rae-1 expression) in WT mice, was not affected. Although it was
shown that activin impairs human NKT cell functions without sig-
nificantly modulating NKG2D receptor expression, little is known
about the effect of activin on γδ T-cell receptors (29). We showed
that γδ T-cells express activin receptors, but we could not detect
increased apoptosis of these cells in the presence of high levels of
activin during DMBA-TPA tumorigenesis. Rather, proliferation of
γδ T-cells was inhibited under these conditions (4). We propose
that activin also attenuates γδ T-cell function after tape-stripping,
probably by inhibiting their proliferation, thereby leading to their
depletion.
In this study, we also demonstrate the pro-inflammatory role
of activin after epithelial barrier injury. Indeed, Il1β mRNA
FIGURE 7 | Il10 and Il17A mRNA expression is increases in OVA-treated
K14-Act mice. Skin biopsies from WT and K14-Act mice, vehicle, or
OVA-treated, were collected and used for RNA isolation and subsequent
generation of cDNA. Real-time PCR was performed using primers specific
for mIl10 (A) and mIl17A (B). Ct values were normalized to expression
levels of the hprt house-keeping gene. The experiment was realized in
groups of 7–10 mice. Results are presented in a scatter graph and mean
values±SEM are shown. Statistically significant differences were
calculated with the Mann–Whitney U -test (p<0.05*, p<0.01**).
levels were increased in OVA-treated mice, and correlated with
macrophage accumulation at the site of the treatment. This was
consistent with previous reports demonstrating that Il1β and
Tnfa are the first cytokines induced after mechanical injury and
epicutaneous sensitization (20, 28, 46). In fact, activin overex-
pression triggers an inflammatory response in the mice treated
only with saline, suggesting that they are more susceptible to
mechanical disruption of the epidermal barrier. Indeed, activin
A is a component of the innate immune response and triggers
pro-inflammatory cytokine secretion in experimental inflamma-
tion (47). Immune responses involve very diverse and complex
molecular mechanisms and cell types, and depend on the nature
of “aggression,” in order to protect the organism. Activin plays
a central role in defense and is controlled by a well-defined cell
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and cytokine milieu (5). Accordingly, activin A’s pro-inflammatory
effect is dose and anatomical site-dependent (25, 48) and linked
to the genetic background. CD1 K14-Act mice present sponta-
neous eye inflammation and periocular skin lesions at 5–6 months
after birth. When backcrossed into an inbred background, such
as BALB/c, the inflammatory lesions emerged earlier and also
appeared at other body sites, and these manifestations were accel-
erated with generations. Skin biopsies from the affected regions of
BALB/c K14-Act mice showed macrophage and neutrophil accu-
mulation, but absence of eosinophils (MK and DH unpublished
observations).
In sum, we showed that activin protects from antigen-induced
dermatitis in skin through modulation of immune responses
after epicutaneous sensitization. Our results suggest that activin
intervenes in at least two ways: (a) To favor secretion of pro-
inflammatory cytokines after mechanical barrier disruption, and
(b) to inhibit Th2-polarization and IgE generation. Further exper-
iments in our model, including short OVA-epicutaneous sensiti-
zation followed by restimulation of DLN cells with OVA ex vivo,
may allow to further dissect the mechanism through which activin
prevents antigen-induced immune responses in skin, and to focus
on early time points.
Activin bioavailability and activity are tightly controlled by
a complex network of secreted and intracellular molecules. The
signals initiated by activin reach gene targets through a sophisti-
cated pathway also firmly regulated at different levels, from the
membrane to the nuclear level. Exhaustive analyses dissecting
this molecular network in skin are necessary in order to con-
sider activin or downstream mediators as successful candidates in
the field of treatment for atopic diseases, ruling out activin’s pro-
fibrotic, pro-inflammatory, and in particular its pro-tumorigenic
effects.
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